SYR1 Feb 2011 21:09
Following a third-quarter interim management statement, Singer Capital Markets retained its "fair value recommendation on Synergy Health (SYR), the decontamination and sterile services provider, with a 839p target price. The broker thinks the group is a fundamentally sound, well-run business with an attractive outlook. It continues to believe that the outlook of the firm is improving and that, from financial year 2013, investors will start to see the benefits of the move into China and the current attractive bid book. That said, Singer currently sees the shares as fairly valued but thinks that any weakness in the share price would be an attractive opportunity for investors. Shares in Synergy inched ahead 6.5p to 891p.